Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

7 Juicy Acquisition Targets in Biopharma for 2017

2016 was not a banner year for M&A in the biopharma industry compared to 2014 and 2015. BioPharmaDIVE looks at seven potential acquisition targets for 2017.

Read More »

Bristol-Myers Squibb, PsiOxus Therapeutics Reach Deal for “Armed” Oncolytic Virus

PsiOxus Therapeutics Ltd. agreed to grant Bristol-Myers Squibb Co. exclusive worldwide rights to NG-348, a pre-clinical stage, “armed” oncolytic virus with the goal of addressing solid tumors.

Read More »

John Kamp: Trump administration promises change for health marketing

Although virtually no one in the urban bubble where biopharmaceutical companies reside expected it to happen, Donald Trump won. So, now what?

Read More »

Sanofi Pasteur Abandons Bladder Cancer Drug

Sanofi Pasteur in an email to urologists informed physicians and patients that it will stop manufacturing TheraCys, BCG Live, for bladder cancer recurrence.

Read More »

Trump Promises to “Reform the FDA”

The President-Elect Donald Trump Administration has a new website and has updated – sort of – Trump’s intended policies for healthcare and biopharma.

Read More »

One Fine Specimen: Where Biopharma Competitiveness Really Begins

Before there are new therapies to set a firm apart, there is a far more fundamental need that competitiveness will ultimately hinge on: high-quality, diversified, annotated human biospecimens.

Read More »

WikiLeaks: Clinton Emails Expose Biopharma Chatter

The ninth batch of presidential candidate Hillary Clinton’s emails released by WikiLeaks has some biopharma gossip that includes Clinton’s team discussing the FDA’s commissioner and it’s so-called “war on pharma.”

Read More »

Boehringer boosts immune-oncology pipeline

Boehringer Ingelheim and ViraTherapeutics will jointly develop a next-generation oncolytic virus therapy platform and investigate ViraTherapeutics’ lead candidate.

Read More »

Biogen to Test Anavex’s Lead Drug Candidate

Biogen will test Anavex Life Sciences’ lead drug candidate, ANAVEX 2-73, in an oligodendrocyte precursor cell (OPC) differentiation assay.

Read More »

Akarna Therapeutics acquired by Allergan

Akarna Therapeutics Ltd. announced that it has been acquired by Allergan plc. Allergan obtains rights to AKN-083, Akarna’s lead product candidate for the potential treatment of non-alcoholic steatohepatitis (NASH) and other liver diseases.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

August 2019 Focus: AI, AR/VR, Top 200 Medicines, Lions Health Takeaways, and more!


Ad Right Bottom